Bioavailable Testosterone by Age: How to Interpret Your Lab Results by Decade of Life

What Bioavailable Testosterone Actually Measures

Bioavailable testosterone represents the portion of circulating testosterone that can enter cells and activate androgen receptors. About 44% of total testosterone in the bloodstream binds loosely to albumin, about 2-3% circulates free, and roughly 54% is tightly bound to SHBG and largely unavailable to tissues. Bioavailable testosterone equals the free fraction plus the albumin-bound fraction.

Why Total Testosterone Alone Is Often Insufficient

A man with a total testosterone of 450 ng/dL might have perfectly normal bioavailable testosterone, or he might have significant androgen deficiency. The difference depends on SHBG. When SHBG is elevated, as it is in older men, men with liver disease, or men taking certain medications, a larger share of testosterone is sequestered and unavailable.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We suggest measuring free or bioavailable testosterone levels when total testosterone levels are near the lower limit of normal, because total testosterone levels may be misleading in some conditions that alter SHBG."

How the Vermeulen Equation Works

Most labs report bioavailable testosterone as a calculated value rather than a directly measured one. The Vermeulen equation uses total testosterone, SHBG, and a fixed albumin concentration (4.3 g/dL) to estimate free and bioavailable fractions. Vermeulen et al. (1999) validated this calculation against equilibrium dialysis, the gold-standard direct measurement, and found strong agreement across a wide testosterone range.

Direct measurement by equilibrium dialysis or ultrafiltration exists but is expensive and not standardized across labs. The Vermeulen calculation, when run on a reliable total T and SHBG assay, is the practical standard for clinical practice.

The Physiology of Age-Related Testosterone Decline

Total testosterone falls roughly 1-2% per year after age 30 in men. Bioavailable testosterone falls faster, dropping approximately 2-3% per year, because SHBG rises simultaneously. The Baltimore Longitudinal Study of Aging documented this dual decline, showing that by age 70, fewer than 10% of men have testosterone levels typical of a 25-year-old.

SHBG: The Central Variable

SHBG is a glycoprotein produced by the liver. Its synthesis increases with age, estrogen exposure, hyperthyroidism, and liver disease. It decreases with obesity, insulin resistance, hypothyroidism, and exogenous androgens. Because SHBG binds testosterone with high affinity, even a modest rise in SHBG can substantially lower bioavailable T without changing total T.

A study in the Journal of Clinical Endocrinology and Metabolism (N=890 men) found that SHBG increased by a mean of 1.6% per year between ages 40 and 70. Over 30 years, that compounds into a near-doubling of SHBG, which can cut bioavailable testosterone roughly in half even if total testosterone remains stable.

Luteinizing Hormone, Testicular Function, and Aging

The decline in bioavailable testosterone is not purely a SHBG story. Testicular Leydig cell mass decreases with age, and hypothalamic-pituitary pulsatility becomes less vigorous. Harman et al. (2001) showed that both free and bioavailable testosterone declined significantly in longitudinal follow-up, independent of SHBG changes, confirming a true decrease in production rather than only redistribution among binding proteins.

Decade-by-Decade Reference Ranges in Men

Reference intervals for bioavailable testosterone vary somewhat by assay and population studied. The figures below reflect values from peer-reviewed population studies and should be interpreted in the context of symptoms, not as absolute cutoffs.

Ages 20-29

This is the physiologic peak. Bioavailable testosterone in healthy men aged 20-29 ranges approximately 83-257 ng/dL based on data from Travison et al. Published in the Journal of Clinical Endocrinology and Metabolism. SHBG is at its lifetime low, and free testosterone also peaks. Clinical androgen deficiency in this age group nearly always reflects primary testicular failure, pituitary pathology, or severe systemic illness rather than aging.

Ages 30-39

Decline begins, though most men remain asymptomatic. Bioavailable testosterone typically spans 72-235 ng/dL. The European Male Ageing Study (EMAS), which enrolled 3,369 men across eight countries, characterized late-onset hypogonadism and found that sexual symptoms (reduced morning erections, decreased libido, erectile dysfunction) correlated most strongly with bioavailable testosterone below 64 ng/dL in this age range. Lifestyle factors including obesity and poor sleep have their largest modifiable impact in the 30s.

Ages 40-49

SHBG begins its meaningful ascent in this decade. Bioavailable testosterone typically falls into the 60-210 ng/dL range, with the lower half of this range increasingly symptomatic for many men. A cross-sectional analysis in the Massachusetts Male Aging Study found that men in the lowest quartile of bioavailable testosterone in their 40s reported significantly higher rates of fatigue, mood disruption, and reduced muscle mass than age-matched peers in the upper two quartiles.

Ages 50-59

The 50s are when the clinical gap between total T and bioavailable T becomes most diagnostically important. Total testosterone may read 380-420 ng/dL, well within the conventional "normal" range, while bioavailable testosterone sits at 55-70 ng/dL due to elevated SHBG. Typical bioavailable testosterone for this decade runs approximately 50-175 ng/dL. The Endocrine Society notes that evaluation for hypogonadism is appropriate when bioavailable T falls below 70 ng/dL in a symptomatic man, regardless of total T.

Ages 60-69

Bioavailable testosterone in healthy 60-69-year-old men typically spans 40-115 ng/dL. At this range, bone mineral density, lean body mass, and metabolic health begin to show measurable differences between men in the upper and lower thirds of the distribution. The Testosterone Trials (TTrials), which enrolled 788 men aged 65 and older with total testosterone below 275 ng/dL, demonstrated that testosterone therapy improved sexual function, bone mineral density, and anemia compared to placebo. These results apply directly to a population where low bioavailable testosterone, not just low total T, drove enrollment criteria.

Ages 70 and Older

Reference ranges for men 70 and older reflect population norms in the range of 30-90 ng/dL bioavailable testosterone. Below 40 ng/dL in a symptomatic man is a clinically significant finding at any age. Bhasin et al. In the New England Journal of Medicine (2010) confirmed that testosterone therapy in older hypogonadal men improved strength and bone density, though the trial was stopped early over cardiovascular concerns that subsequent larger trials did not replicate.

Bioavailable Testosterone Reference Ranges in Women

Women produce testosterone primarily in the ovaries and adrenal glands. Normal bioavailable testosterone in premenopausal women aged 18-50 runs approximately 0.5-8.5 ng/dL, with peak values in the mid-20s. After menopause, both total testosterone and bioavailable testosterone decline, though SHBG may rise with oral estrogen use, further suppressing bioavailable levels.

Symptoms of Low Bioavailable Testosterone in Women

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) recognizes hypoactive sexual desire disorder (HSDD) as the primary evidence-based indication for testosterone therapy in women. The panel noted that serum testosterone levels do not reliably correlate with symptoms, but bioavailable T below the premenopausal reference range, combined with HSDD symptoms, supports a therapeutic trial.

Oral Estrogen and SHBG Suppression

Women taking oral estrogen therapy (such as oral estradiol or combined oral contraceptives) often experience a significant rise in SHBG, which can suppress bioavailable testosterone enough to produce symptoms of androgen deficiency even when total testosterone is normal. Switching to transdermal estradiol avoids the hepatic first-pass SHBG induction. A randomized crossover study confirmed that transdermal estradiol produces substantially lower SHBG compared to oral administration.

What "Optimal" Means Versus What "Normal" Means

Reference ranges on lab reports represent the middle 95% of the general population. They include people with undiagnosed illness, sedentary lifestyles, and metabolic syndrome. An individual near the bottom of the reference range may be technically "normal" and still clearly symptomatic and suboptimal.

Longevity Medicine Perspective

The longevity medicine community, drawing on data from population studies including the InCHIANTI Study of aging, generally targets the upper tertile of the age-specific bioavailable testosterone reference range as optimal. For men under 50, that corresponds roughly to 130-200 ng/dL bioavailable testosterone. For men 50-65, approximately 100-160 ng/dL. These are not FDA-approved treatment thresholds, and physicians vary in their approach.

Symptom Correlation Matters More Than a Single Number

A man with bioavailable testosterone of 85 ng/dL and no symptoms does not require treatment. A man at 85 ng/dL with reduced libido, fatigue, decreased morning erections, and loss of lean mass has a clinically actionable picture. The EMAS sexual function criteria, validated in 3,369 men, require at least three sexual symptoms plus a total testosterone below 11 nmol/L (317 ng/dL) or a free testosterone below 220 pmol/L for a diagnosis of late-onset hypogonadism. No single-number cutoff replaces clinical judgment.

How to Optimize the Bioavailable Testosterone Test

Getting an accurate result requires more than ordering the right panels.

Pre-Analytic Variables

Draw blood in the morning, between 7 and 10 a.m. Testosterone peaks during this window. Afternoon draws can underestimate levels by 20-30%. Bremner et al. Demonstrated a diurnal variation of approximately 35% between morning peak and late-afternoon nadir in healthy young men. Fasting is not required but avoiding a high-fat meal before the draw reduces analytical interference.

What to Order Alongside Bioavailable T

The minimum useful panel includes total testosterone, SHBG, and albumin. For men, add LH and FSH to distinguish primary from secondary hypogonadism. For comprehensive metabolic context, add a complete metabolic panel (for liver function, which influences SHBG) and HbA1c (insulin resistance suppresses SHBG and total T independently). If symptoms include gynecomastia or feminization, add estradiol.

Interpreting Results on TRT

Men already on testosterone replacement therapy should not expect bioavailable T to mirror natural levels, because exogenous testosterone suppresses LH and therefore SHBG often falls. Bioavailable T may rise disproportionately relative to the dose. Target monitoring at trough (before the next injection or application), and check at 3 months after any dose change. The Endocrine Society recommends targeting mid-normal total testosterone at trough and using bioavailable T to confirm adequacy when SHBG is abnormal.

Conditions That Alter Bioavailable Testosterone Independent of Age

Several conditions shift bioavailable T dramatically.

Obesity suppresses SHBG and total T, but may raise free T disproportionately due to low SHBG. Insulin resistance decreases hepatic SHBG synthesis, so obese men often have low total T with relatively preserved or even elevated free T. This makes bioavailable T the more meaningful metric in metabolic syndrome.

Type 2 diabetes is associated with both lower total and lower free testosterone. The TTrials sexual function sub-study included substantial numbers of diabetic men and confirmed that testosterone therapy improved sexual function even when controlling for metabolic status.

Liver cirrhosis elevates SHBG dramatically, often causing bioavailable T to fall despite preserved or elevated total T. Thyroid disease has bidirectional effects: hyperthyroidism raises SHBG, hypothyroidism lowers it.

When Treatment Should Be Considered

The decision to treat is never based on a lab value alone. The Endocrine Society 2018 Guideline recommends testosterone therapy in men who have both:

1. Unequivocal symptoms and signs of androgen deficiency.
2. Confirmed low testosterone on at least two morning blood draws.

The guideline states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness, because testosterone levels may be transiently low during illness and recover after resolution."

Bioavailable testosterone below 70 ng/dL in a symptomatic man represents a threshold many hormone-specialist physicians find actionable. Values between 70 and 100 ng/dL in men with symptoms warrant a shared clinical decision with attention to reversible causes (weight loss, improved sleep, alcohol reduction) before starting therapy.